Effect of an occlusal splint on sleep bruxism in children in a pilot study with a short-term follow up

2013 ◽  
Vol 17 (4) ◽  
pp. 418-422 ◽  
Author(s):  
Lilian Chrystiane Giannasi ◽  
Israel Reis Santos ◽  
Thays Almeida Alfaya ◽  
Sandra Kalil Bussadori ◽  
Luis Vicente Franco de Oliveira
2020 ◽  
Vol 58 (10) ◽  
pp. e175
Author(s):  
Daniel Bradley ◽  
Calum Honeyman ◽  
Vinod Patel ◽  
Julian Zeolla ◽  
Lucy Lester ◽  
...  

2015 ◽  
Vol 60 (2) ◽  
pp. 833-837 ◽  
Author(s):  
María Gabriela Álvarez ◽  
Yolanda Hernández ◽  
Graciela Bertocchi ◽  
Marisa Fernández ◽  
Bruno Lococo ◽  
...  

ABSTRACTThere is a clinical need to test new schemes of benznidazole administration that are expected to be at least as effective as the current therapeutic scheme but safer. This study assessed a new scheme of benznidazole administration in chronic Chagas disease patients. A pilot study with intermittent doses of benznidazole at 5 mg/kg/day in two daily doses every 5 days for a total of 60 days was designed. The main criterion of response was the comparison of quantitative PCR (qPCR) findings prior to and 1 week after the end of treatment. The safety profile was assessed by the rate of suspensions and severity of adverse effects. Twenty patients were analyzed for safety, while qPCR was tested for 17 of them. The average age was 43 ± 7.9 years; 55% were female. Sixty-five percent of treated subjects showed detectable qPCR results prior to treatment of 1.45 (0.63 to 2.81) and 2.1 (1.18 to 2.78) parasitic equivalents per milliliter of blood (par.eq/ml) for kinetoplastic DNA (kDNA) qPCR and nuclear repetitive sequence satellite DNA (SatDNA) qPCR, respectively. One patient showed detectable PCR at the end of treatment (1/17), corresponding to 6% treatment failure, compared with 11/17 (65%) patients pretreatment (P= 0.01). Adverse effects were present in 10/20 (50%) patients, but in only one case was treatment suspended. Eight patients showed mild adverse effects, whereas moderate reactions with increased liver enzymes were observed in two patients. The main accomplishment of this pilot study is the promising low rate of treatment suspension. Intermittent administration of benznidazole emerges a new potential therapeutic scheme, the efficacy of which should be confirmed by long-term assessment posttreatment.


2022 ◽  
Vol 12 (1) ◽  
pp. 431
Author(s):  
Gema Corpus ◽  
David P. Piñero

This pseudo-experimental, prospective, and longitudinal pilot study was conducted to characterize the optical and visual changes occurring in the short-term wear of a hydrophilic contact lens (CL) based on extended focus technology (EDOF). A total of 30 eyes of 15 children (age, 6–16 years) were fitted with the EDOF CL Mylo (Mark’ennovy Care SL), performing an exhaustive follow-up for one month evaluating changes in visual acuity (VA), accommodation, binocularity, ocular aberrometry, visual quality, pupillometry, keratometry and biometry. Far and near VA with the CL improved progressively (p < 0.001), obtaining mean final binocular values of −0.08 ± 0.01 and −0.07 ± 0.01 LogMAR, respectively. There was a mean reduction in the accommodative LAG of 0.30 D (p < 0.001), without associated alterations in the magnitude of the phoria and fusional vergences (p ≥ 0.066). A controlled but statistically significant increase (p ≤ 0.005) of ocular high order aberration (HOA) root mean square (RMS), primary coma RMS, primary spherical aberration Zernike term and secondary astigmatism RMS was found with the CL wear. In conclusion, the EDOF CL evaluated provides adequate visual acuity and quality, with associated increased of several HOAs and a trend to reduction in the accommodative LAG that should be confirmed in future studies.


2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 21-21
Author(s):  
M. J. Janicek ◽  
V. M. Camaya

21 Background: The shift from the use of BrMR for confirmation of known abnormality to the screening mode in problematic breast is associated with higher frequency of probably benign findings. Some of them still require biopsy, with or without close BrMR follow up (f/u), some may remain on observation only. Our pilot study analyzed clinical outcomes of MR-Bi3 pts and added value of close BrMR f/u. Proportion of MR-Bi3, some after “second look ultrasound” (2ndUS) with or without biopsy could be used among other monitors of BrMR practices. Methods: We reviewed BIRAD categories assigned to all 743 BrMRs done in period of year 2007 in our specialized breast imaging practice with dedicated BrMR (Aurora) system and full complement of diagnostic and interventional modalities. Frequency of MR-Bi3 and studies resulting in MR-Bi3 or biopsies after 2ndUS were analyzed. With benefit of 3 year clinical data, the outcome of patients on such short term f/u schedule was reviewed. Results: MR-Bi3 was assigned to 40 (5.4%) of our BrMRs on the initial evaluation, all of them yielded benign findings on follow up. Additional 26.2% of our studies required 2ndUS. After 2ndUS, 40% of these pts were converted to Bi4+5, continued with image guided biopsy with cancer detected in 35% of those. Remaining 60% of 2ndUS yielded “probably benign findings”, MR-Bi3, which means that total of 21.6% of our BrMRs remained on close f/u schedule with MRI. There were no additional delayed findings of malignancy in this group. Single additional BrMR was sufficient to confirm benign findings only in 47% of cases, 24% of patients required multiple BrMRs at 6 month intervals, remaining patients were followed by other modalities. Conclusions: Utilization of MR-Bi3 category reflects readers' confidence avoiding or justifying biopsies for border line findings. Targeted use of 2ndUS helps to identify patients who benefit from biopsy rather than close f/u. Proportion of repeated Bi3 and outcome of Bi3 could become valuable QA indices for monitoring of BrMR practices. Only in small proportion of cases, the use of Bi3 was not contributory, particularly in case of repeated BrMRs for the same abnormality.


BMC Surgery ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jie Wang ◽  
Li Min ◽  
Minxun Lu ◽  
Yuqi Zhang ◽  
Jingqi Lin ◽  
...  

Abstract Background The aims of this pilot study were (1) to assess the efficacy of 3D-printed custom-made hemipelvic endoprosthesis in restoring the natural location of acetabulum for normal bodyweight transmission; (2) to evaluate the short-term function of the revision with this endoprosthesis and (3) to identify short-term complications associated with the use of this endoprosthesis. Methods Between February 2017 and December 2017, seven patients received revision with 3D-printed custom-made hemipelvic endoprosthesis. The body weight moment arm (BWMA) and cup height discrepancy (CHD) after primary and revisional surgery were analyzed to assess acetabulum location with plain radiography. After a median follow-up duration of 29 months (range 24–34), the function was evaluated with the Musculoskeletal Tumor Society (MSTS-93) score and Harris hip score (HHS). Complications were recorded by chart review. Results The acetabulum locations were deemed reasonable, as evaluated by median BWMA (primary vs. revision, 10 cm vs. 10 cm) and median CHD (primary vs. revision, 10 mm vs. 8 mm). The median MSTS-93 score and HHS score were 21 (range 18–23) and 78 (range 75–82) after the revision. No short or mid-term complication was observed in the follow-up of this series. Conclusions Revision with 3D-printed custom-made hemipelvic endoprostheses benefited in reconstructing stable pelvic ring and natural bodyweight transmission for patients encountering the aseptic loosening and fracture of modular hemipelvic endoprosthesis. The revision surgery and appropriate rehabilitation program improved patients’ function to a median MSTS score of 22 and pain-free ambulation. The incidence of the complications was low via this individualized workflow.


Sign in / Sign up

Export Citation Format

Share Document